Prevalence of inappropriate use of nirmatrelvir-ritonavir antiviral therapy in hospitalized patients: A multi-centre retrospective study in China.

ABSTRACT:

Background

Nirmatrelvir-ritonavir (NMVr) is a recently developed antiviral agent for treating coronavirus disease 2019 (COVID-19); however, data describing its appropriate use are scarce. This study examined the prevalence of inappropriate use of NMVr in a Chinese hospital setting.

Methods

A multi-centre retrospective chart review was performed for all hospitalized patients who received NMVr between 15 December 2022 and 15 February 2023 in four university-affiliated hospitals in Hangzhou, China. A multi-disciplinary team of experts developed the evaluation criteria. A group of senior clinical pharmacists examined and verified the suitability of NMVr prescriptions.

Results

In total, 247 patients received NMVr during the study period, of which 13.4% (n=31) met all the c

SUBMITTER: Shi C 

PROVIDER: S-EPMC10197429 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature